MDR-TB TREATMENT UPDATE
Rifampicin-resistant tuberculosis (RR-TB) accounts for an expanding proportion of incident global TB cases and is a major barrier to global tuberculosis control. Conventional therapy for RR-TB is more toxic, less effective, and much more costly than drug-susceptible TB. Treatment success has been co...
Збережено в:
| Автор: | |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2023-05-01
|
| Серія: | International Journal of Infectious Diseases |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S1201971223002503 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|